LOS ALTOS, Calif., May 18, 2015 /PRNewswire-iReach/ -- AbGenomics International announced the start of a phase-Ib/IIa clinical trial using the lead compound Neihulizumab (AbGn-168H) to treat steroid refractory acute GvHD (aGvHD). This investigator-initiated trial is sponsored by Stanford University in its nation's leading bone marrow transplant program. The primary objective of the study is to evaluate the safety and efficacy of AbGn-168H in patients with steroid refractory aGvHD in the post-allogeneic transplantation setting. aGVHD is a major complication of hematopoietic cell transplantation (HCT) that accounts for most non-relapse mortality and limits the use of HCT. Steroid refractory aGVHD carries an especially high mortality of between 60-85%. According to key opinion leaders in this field, a huge unmet medical need of aGvHD needs to be satisfied under the existing therapies.
Logo - http://photos.prnewswire.com/prnh/20150515/216371
Prior to the aGvHD trial, the proof of clinical efficacy and safety of AbGn-168H, a humanized monoclonal antibody, has been well demonstrated in a randomized, multicenter, double-blind, placebo-controlled phase II trial in patients with moderate-to-severe plaque psoriasis. Most recently, AbGenomics has also initiated an open-label, multi-center phase II study for psoriatic arthritis. The company is dedicated to bring forth this potential game-changing therapeutic candidate for the treatment of various inflammatory diseases.
About AbGenomics (www.abgenomics.com)
AbGenomics International Inc. (AbG) is an innovative, clinical-stage biopharmaceutical company developing targeted antibody therapeutics for the treatment of immune-mediated inflammatory diseases and cancers. Headquartered in San Francisco Bay Area, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The lead candidate for anti-inflammatory therapy, Neihulizumab (AbGn-168H), is a therapeutic antibody with potential of long lasting drug-free remission and less risk concern for infections. In company's oncology portfolio, the biosuperior antibody drug conjugate (ADC), featured on their superior efficacy and safety profiles, has proved to show a sustainable competitive advantage over our competitors. The Company's strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company's compounds.
Note on Forward-Looking Statements
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.
Media Contact:RUTH LI, ABGENOMICS INTERNATIONAL INC, 6503824568, ABG@ABGENOMICS.COM
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE AbGenomics International Inc.
Help employers find you! Check out all the jobs and post your resume.
